Claims for Patent: 11,179,402

Summary for Patent: 11,179,402

Title:	Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
Abstract:	A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
Inventor(s):	Dudley; Robert E. (Murfreesboro, TN), Constantinides; Panayiotis P. (Gurnee, IL)
Assignee:	Clarus Therapeutics, Inc. (Northbrook, IL)
Application Number:	15/814,162
Patent Claims:	1. A pharmaceutical composition suitable for oral administration to a mammalian subject comprising: (a) 15-20 percent by weight of testosterone undecanoate; (b) 5-20 percent by weight of hydrophilic surfactant; and (c) 20-80 percent by weight of lipophilic surfactant which is a C.sub.14-C.sub.24 fatty acid; wherein said composition further comprises an antioxidant; wherein said composition is free of monohydric alcohol wherein the formulation consists of a liquid encased in a capsule, and wherein administration of the formulation twice daily provides a serum concentration of testosterone ranging from about 300 to about 1100 ng/dL. 2. The pharmaceutical composition as recited in claim 1, wherein said composition further comprises one or more digestible oils chosen from borage oil and peppermint oil. 3. The pharmaceutical composition as recited in claim 1, wherein said composition exhibits a percent (%) in vitro dissolution profile in phosphate buffered saline, which indicates release from the composition of substantially all of the testosterone ester within about 2 hours. 4. The pharmaceutical composition as recited in claim 1, wherein said the hydrophilic surfactant exhibits an HLB of 10 to 45. 5. The pharmaceutical composition of claim 4, wherein the hydrophilic surfactant is chosen from polyoxyethylene sorbitan fatty acid esters, hydrogenated castor oil ethoxylates, PEG mono- and di-esters of palmitic and stearic acids, fatty acid ethoxylates, and combinations thereof. 6. The pharmaceutical composition of claim 5, wherein the hydrophilic surfactant is a hydrogenated castor oil ethoxylate. 7. The pharmaceutical composition of claim 1, in which the lipophilic surfactant exhibits an HLB of less than 10. 8. The pharmaceutical composition of claim 7, in which the lipophilic surfactant exhibits an HLB of less than 5. 9. The pharmaceutical composition of claim 8, in which the lipophilic surfactant exhibits an HLB of 1 to 2. 10. The pharmaceutical composition of claim 7, wherein the lipophilic surfactant is chosen from myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, and linolenic acid. 11. The pharmaceutical composition of claim 10, wherein said lipophilic surfactant is oleic acid. 12. A pharmaceutical composition suitable for oral administration to a mammalian subject comprising: 15-20 percent by weight of testosterone undecanoate; 5-20 percent by weight of hydrophilic surfactant having a HLB of 10-45 and selected from the group consisting of polyoxyethylene sorbitan fatty acid esters, hydrogenated castor oil ethoxylates, PEG mono- and di-esters of palmitic and stearic acids, fatty acid ethoxylates, and combinations thereof; and 20-80 percent by weight of lipophilic surfactant which is a C14-C24 fatty acid and is selected from the group consisting of myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, linolenic acid, and combinations thereof; at least one digestible oil chosen from borage oil and peppermint oil; and at least one antioxidant; wherein said composition is free of monohydric alcohol wherein the formulation consists of a liquid encased in a capsule, and wherein administration of the formulation twice daily provides a serum concentration of testosterone ranging from about 300 to about 1100 ng/dL. 13. The pharmaceutical composition of claim 12, wherein the hydrophilic surfactant is a hydrogenated castor oil ethoxylate. 14. The pharmaceutical formulation of claim 1, wherein the formulation is self-emulsifying. 15. The pharmaceutical formulation of claim 12, wherein the formulation is self-emulsifying. 16. The pharmaceutical formulation of claim 1, wherein the at least one antioxidant is chosen from ascorbyl palmitate and butylhydroxytoluene (BHT). 17. The pharmaceutical formulation of claim 12, wherein the at least one antioxidant is chosen from ascorbyl palmitate and butylhydroxytoluene (BHT).